Halozyme Therapeutics (HALO) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $130.34 --0%
EPS Growth %: +32.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SENEA, XFOR, MG, More
EPS Growth %: +32.6%
Financial Fact:
Total revenues: 31.85M
Today's EPS Names:
SENEA, XFOR, MG, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.8 million versus the consensus estimate of $31.76 million.
GUIDANCE:
Halozyme Therapeutics sees FY2017 revenue of $115-130 million, versus the consensus of $132.6 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 1stdibs.Com, Inc. (DIBS) Tops Q3 EPS by 2c ; Offers Guidance
- Bob's Discount Furniture, Inc. (BOBS) Reports Q3 EPS of $0.28 ; Offers Guidance
- Unity Software Inc. (U) Tops Q3 EPS by 41c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
